FDA grants orphan-drug status to Amira's drug for lung fibrosis

04/20/2011 | Xconomy

Amira Pharmaceuticals' AM152, a drug candidate for idiopathic pulmonary fibrosis, was given orphan-drug designation by the FDA. The status provides Amira seven years of market exclusivity.

View Full Article in:

Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC